
Fei Liu

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9601971/publications.pdf Version: 2024-02-01



Feilui

#	Article	IF	CITATIONS
1	miR-132 mediates cell permeability and migration by targeting occludin in high-glucose -induced ARPE-19 cells. Endocrine Journal, 2021, 68, 531-541.	1.6	5
2	Suppressing long noncoding RNA OGRU ameliorates diabetic retinopathy by inhibition of oxidative stress and inflammation via miR-320/USP14 axis. Free Radical Biology and Medicine, 2021, 169, 361-381.	2.9	27
3	MiR-195 inhibits the ubiquitination and degradation of YY1 by Smurf2, and induces EMT and cell permeability of retinal pigment epithelial cells. Cell Death and Disease, 2021, 12, 708.	6.3	25
4	A study of dry eye after cataract surgery in MGD patients. International Ophthalmology, 2020, 40, 1277-1284.	1.4	10
5	PRMT7 promotes the growth of renal cell carcinoma through modulating the β-catenin/C-MYC axis. International Journal of Biochemistry and Cell Biology, 2020, 120, 105686.	2.8	23
6	Identification of a novel PAX6 mutation in a Chinese family with aniridia. BMC Ophthalmology, 2019, 19, 10.	1.4	3
7	Analytical factors and treatment methods of renal parenchyma perforation after ureteral double-J stenting. Asian Journal of Surgery, 2019, 42, 717-720.	0.4	Ο
8	Musashi1 promotes tumor metastasis and is a prognostic marker for renal carcinoma. International Journal of Clinical and Experimental Pathology, 2019, 12, 313-319.	0.5	3
9	Regulation of TLR4 expression mediates the attenuating effect of erythropoietin on inflammation and myocardial fibrosis in rat heart. International Journal of Molecular Medicine, 2018, 42, 1436-1444.	4.0	23
10	The long non-coding RNA NEAT1 enhances epithelial-to-mesenchymal transition and chemoresistance via the miR-34a/c-Met axis in renal cell carcinoma. Oncotarget, 2017, 8, 62927-62938.	1.8	58
11	Anti-cancer and Sensibilisation Effect of Triptolide on Human Epithelial Ovarian Cancer. Journal of Cancer, 2016, 7, 2093-2099.	2.5	42
12	miR-144-3p serves as a tumor suppressor for renal cell carcinoma and inhibits its invasion and metastasis by targeting MAP3K8. Biochemical and Biophysical Research Communications, 2016, 480, 87-93.	2.1	58
13	VEGF pathway-targeted therapy for advanced renal cell carcinoma: A meta-analysis of randomized controlled trials. Journal of Huazhong University of Science and Technology [Medical Sciences], 2011, 31, 799-806.	1.0	4